Author Archive: BIOtechNOW Editor

Delivering on the Promise of Personalized Medicine

185x185_ad_btn_home

As sequencing moves out of the lab and into the clinic, a host of players must get involved to make our collective promises of personalized medicine a reality. CEOs, entrepreneurs, researchers, clinicians, regulators and payers need to work together to take on the next challenges in the implementation of personalized medicine. Some of those challenges include: Cost vs. Benefit: How do we define and benefit from transformational technologies? Form vs. Function: What about the less Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

The Future of Biodefense: Will Public-Private Partnerships Continue?

commercial-jenn

Ten years ago, in the wake of the 2001 anthrax attacks, the U.S. government set out on a bold path to improve the country’s preparedness for bioterrorism by developing and stockpiling new drugs and vaccines to protect Americans from health emergencies.  Individuals from both political parties – many who had experienced bioterror first hand – worked together to harness the power of innovative science and tackle this national security threat. The ten year initiative was Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Inter Partes Review – a Useful Tool for Overcoming Freedom-to-Operate Obstacles

Basic CMYK

By Eric K. Steffe, Eldora L. Ellison, Ph.D., Todd Spalding, and Deborah A. Sterling, Ph.D. For companies facing freedom-to-operate obstacles, the AIA provides a number of tools for dealing with troublesome patents.  While proceeding at risk in the face of such patents sometimes make sense, inter partes review (IPR) provides a viable option for challenging them and should be considered as a valuable addition to one’s freedom-to-operate toolbox. Inter partes reexamination (IPX), which (bio)pharma used Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

Academics to be Featured at the 2013 BIO Alliance Pavilion

BIO International Convention

I think it safe to say that the U.S. biotechnology industry has its R&D roots in the laboratories of great research universities with great science and visionary researchers. These cutting-edge, biology-based research and industry commercialization efforts continue to be the key drivers in moving invention into innovation to heal, fuel and feed the world. Because of this essential knowledge-driven relationship, the 2013 BIO International Convention will again bring together academic and research colleagues to focus Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

SIPO Examiner Workshop: Biotech Patent Practices in the U.S., China and Japan

Great Wall of China - Image by jrover

The biotechnology industry is an invention-intensive industry that relies heavily on the protection of intellectual property, especially patent rights. Patent protection is territorial, and patent practice varies in different jurisdictions. Many foreign biotech companies continue to look at China as an important emerging market, and they increasingly file patent applications in China to develop their global patent portfolios. At the same time, China has made biotechnology one of the eight strategic new technology focuses in Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,